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Abstract 
 The aim of the present study was to study the association of 
metformin dose with peripheral neuropathy in diabetic patients at Jordanian 
Royal Medical Services. A retrospective study was conducted to collect data 
from files of 392 diabetic patients at Jordanian Royal Medical Services. A 
working sheet was created for each patient that included the following 
information: gender, age, peripheral neuropathy, vitamin B12 status, 
metformin use, and metformin dose. Data were analyzed using SPSS version 
20. Data were represented as frequencies and percentages for categorical 
variables such as gender, and vitamin B12 status; means and standard 
deviations for continuous variables such as age. The relationships between 
variables were examined using Chi-Square, and One Way Anova. 
Significance was considered at alpha level <0.05. Study findings showed that 
the prevalence of diabetic peripheral neuropathy among participants was 
about 43%. Vitamin B12 deficiency was about 7%. Diabetic peripheral 
neuropathy was significantly associated with gender (p=0.018). No 
significant associations were observed between peripheral neuropathy and 
vitamin B12 or metformin dose. Taken together,  the  results of the present 
study showed that treatment with metformin did not lead to vitamin B12 
deficiency, although the prevalence of diabetic peripheral neuropathy was 
relatively high (about 43%).  
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Introduction  
    Type 2 diabetes mellitus (DM) is considered as one of the most 
prevalent metabolic diseases at global level, and its prevalence is likely to 
with age and obesity (Butterfield et al., 2014). The functions of several 
organs are deteriorated by DM such as brain (Arnold et al., 2014). 
 Metformin is used widely as anti-diabetic drug (Ruggiero-Lopez et 
al., 1999; Kirpichnikov etal.,2002; Yamagishi et al., 2008; Ma et al., 2015). 
It acts through lowering glucose hepatic production (Derosa et al., 2008). 
Although the mechanisms of metformin action are not well clear, it has been 
recently suggested that to some pleiotropic actions (Chen et al., 2001). 
Among these actions is AMP-activated protein kinase (AMPK) (Steinberg 
and Kemp, 2009). Several roles of AMPK have been involved in DM, 
neuroprotection, anti-inflammation and alteration of oxidative stress 
(Chakraborty et al., 2011; Salminen et al., 2011).    
    It has been indicated to the possibility of inhibition of injury-induced 
neuropathic pain (Melemedjian etal.,2011). In another study, metformin was 
able to reverse mechanical allodynia in lumbar radiculopathy pain in 
experimental models such as rats and mice (Taylor et al.,2013). Furthermore, 
using mouse model showed the potential of metformin to offer protection 
against chemotherapy induced neuropathic pain (Mao-Yingetal.,2014).  
    Other studies showed that long term treatment by metformin lowers 
serum concentration of cyanocobalamine up to 30%, and this may occur in 
approximately in 30% of treated patients (Mazokopakis and Starakis, 2012). 
This process depends on inhibition of cyanocobalamine intrinsic factor 
complex absorption, which depends on calcium, so that it can be treated with 
calcium supplementation (Jager et al., 2010). It has been demonstrated that 
the treatment of metformin is not likely to cause megaloblastic anemia 
except in cases of heavily doses over a long duration (Mazokopakis and 
Starakis, 2012).  
 
Study objectives   
    To study the association of metformin dose with peripheral 
neuropathy in diabetic patients at Jordanian Royal Medical Services. 
 
Methods and subjects  
    This section includes the methods of choice which were involved to 
collect data and to conduct the appropriate statistical analyses.  
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Study design and setting 
    A retrospective design was employed to collect data from study 
participants. The study was conducted at Jordanian Royal Medical Services.  
 
Study sample 
    Study sample included a total of 392 diabetic patients. 
 
Data collection 
    A working sheet for each diabetic patient was created for each 
diabetic patient. The required information were extracted from files of 
patients including age, gender, peripheral neuropathy, metformin use, 
metformin dose, and the status of vitamin B12.  
 
Data analysis 
    All data were entered into excel sheet to obtain the raw data. SPSS 
version 20 was used to analyze data. Categorical variables such as gender 
were presented as frequencies and percentages, while continuous variables 
such as age was presented as mean and standard deviation. The relationships 
between variables were examined using Chi-Square, T test, and One Way 
Anova. Significance was considered at alpha level <0.05. 
 
Results  
General characteristic of participants  
    As it can be demonstrated in table 1, the mean age of study 
participants was 56.18+9.51 years. About 47% were males. The prevalence 
of peripheral neuropathy was approximately 43%. About 85% of diabetic 
patients received metformin treatment, and the mean metformin dose was  
1474.68+906.78 mg/day. Vitamin B12 deficiency was shown among about 
7% of patients. 
Table 1: General characteristic of participants  
Variable  Description  
Age (M+SD) years 56.18+9.51 
Gender (N, %): 
Males 
Females    
 
183 (46.7%) 
209 (53.3%) 
Peripheral neuropathy(N, %): 
Yes  
No   
 
168 (42.9%) 
224 (57.1%) 
Metformin (N, %): 
Yes  
No  
 
331 (84.6%) 
61 (15.6%) 
Metformin dose (M+SD) mg 1474.68+906.78 
Vitamin B12 (N, %): 
Deficiency   
Normal  
 
26 (6.6%) 
366 (93.4%) 
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The relationship between peripheral neuropathy and study variables 
    As it can be seen in table 2, male were more likely to develop 
peripheral neuropathy than females, and this variation was statistically 
significant (p=0.018). No significant variations were observed between 
peripheral neuropathy and each of metformin use (p=0.780) and vitamin B12 
status (p=0.446). 
Table 2: The relationship between peripheral neuropathy and study variables 
Variable                 Peripheral neuropathy P value 
            Yes             No  
N % N % 
Gender  
Males 
Females  
 
90 
78 
 
49.2 
37.3 
 
93 
131 
 
50.8 
62.7 
0.018 
Metformin use  
No  
Yes   
 
143 
25 
 
43.2 
41 
 
188 
36 
 
56.8 
59 
0.780 
Vitamin B12 
Normal  
Deficiency  
 
13 
155 
 
50 
42.3 
 
13 
211 
 
50 
57.7 
0.446 
 
The effects of study variables on peripheral neuropathy 
    In this section, One Way Anova was conducted to examine the 
effects of study variables on peripheral neuropathy. As it can be illustrated in 
table 3, the following variables were examined: age, gender, metformin, 
metformin dose, and vitamin B2. Among these variables, gender was 
significantly associated with peripheral neuropathy (p=0.018), while the 
remaining variables were not statistically associated significantly with 
peripheral neuropathy (p>0.05). 
Table 3: The effects of study variables on peripheral neuropathy 
Variable  Sum of squares DF Mean square F  P-value  
Age  46.14 1 46.164 0.510 0.476 
Gender  1.395 1 1.395 5.66 0.018 
Metformin  0.014 1 0.014 0.103 0.748 
Metformin 
dose  
368333.466 1 368333.466 0.447 0.504 
Vitamin B12 .036 1 .036 0.578 0.448 
 
Discussion 
    The present study showed that the prevalence of peripheral  
neuropathy among diabetic patients was about 43%.  The prevalence of 
peripheral neuropathy in other studies such as the study of Davies et al 
(2006) in which the prevalence of peripheral neuropathy was 26.4%. other 
studies reported the prevalence of peripheral neuropathy to vary from 3% 
(Sorensen, Molyneaux and, Yue, 2002) to 32% (Ziegler etal., 1993).  
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    The findings of our study showed that vitamin B12 deficiency was 
about 93% among diabetic patients. Reviewing the literature showed that the 
prevalence of vitamin B12 deficiency varied from 5.8% to 33% (Pflipsen et 
al., 2009; Qureshi, Ainsworth, and Winocour, 2011;  Reinstatler et al., 2012).  
    The findings of the present study revealed a significant role of gender 
to develop peripheral neuropathy (p=0.018). This finding is not consistent 
with the results of the study of Kodali, Seshaiah, and Kumar (1990) who 
found higher prevalence of peripheral neuropathy among women compared 
with men. 
    No significant association was found between diabetic peripheral 
neuropathy and vitamin B12 deficiency and metformin (p>0.05).  We think, 
based on these findings,  that metformin provides neuroprotection and 
confirm other studies such as Chakraborty et al (2011) and; Salminen et al 
(2011).    
 
Conclusion 
    The  results of the present study showed that treatment with 
metformin does not lead to vitamin B12 deficiency, although the prevalence 
of diabetic peripheral neuropathy was relatively high (about 43%). Diabetic 
peripheral neuropathy was significantly associated with gender (p=0.018). 
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